Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.69 |
| ▸ | KDR | P35968 | 7/20 | 0.60 |
| ▸ | MST1R | Q04912 | 3/20 | 0.60 |
| ▸ | HGF | P14210 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284701 | 0.89 | MET (0.55) | METKDRMST1RHGFJAK2 | |
| SCHEMBL2285815 | 0.88 | MET (0.54) | METKDRMST1RHGFJAK2 | |
| SCHEMBL2285226 | 0.84 | MET (0.62) | METKDRMST1RHGFJAK2 | |
| SCHEMBL2859380 | 0.82 | MET (1.00) | METKDRMST1RHGFJAK2 | |
| SCHEMBL2285261 | 0.81 | MET (0.58) | METKDRMST1RHGFJAK2 | |
| SCHEMBL3560357 | 0.78 | MET (0.66) | METKDRMST1RHGFJAK2 | |
| SCHEMBL3111401 | 0.78 | MET (0.66) | METKDRMST1RHGFJAK2 | |
| SCHEMBL15405892 | 0.77 | MET (0.77) | METKDRMST1RHGFJAK2 | |
| SCHEMBL2281528 | 0.77 | MET (0.44) | METKDRMST1RHGF | |
| SCHEMBL3107124 | 0.76 | MET (0.63) | METKDRMST1RHGFJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885KDR 419/4885MST1R 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.